Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy-Reference-Cited by-同舟云学术

Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy

Published:2012-01-18 Issue:4 Volume:15 Page:427-432
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Ando Takayuki,Hosokawa Ayumu,Kajiura Shinya,Itaya Yuko,Ueda Akira,Fujinami Haruka,Nishikawa Jun,Kobayashi Takashi,Horikawa Naoki,Tsukioka Yuji,Yabushita Kazuhisa,Note Masayuki,Ogawa Kohei,Sugiyama Toshiro

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-011-0135-0.pdf

Reference28 articles.

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33–64.

3. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36:384–92.

4. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.

5. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study;Current Medical Research and Opinion;2024-06-22

2. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results;The Breast;2023-04

3. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma;Cancer Medicine;2022-09-02

4. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO;European Journal of Cancer;2022-04

5. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy;International Journal of Clinical Oncology;2021-01-03